CEL-SCI Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CVM NYSE American 2836 cel-sci.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CEL-SCI Corporation

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients - Jun 18th, 2025 7:00 am
CEL-SCI Announces Closing of Public Offering - May 23rd, 2025 2:05 pm
CEL-SCI Announces Pricing of Public Offering - May 21st, 2025 6:14 pm
CEL-SCI Announces Proposed Public Offering - May 21st, 2025 2:05 pm
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia - May 21st, 2025 6:00 am
CEL-SCI Announces Combination of Common Stock - May 19th, 2025 12:40 pm
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - May 15th, 2025 7:00 am
Cel-Sci: Fiscal Q2 Earnings Snapshot - May 14th, 2025 5:30 pm
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Apr 23rd, 2025 6:30 am
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses - Apr 8th, 2025 7:51 am
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Mar 24th, 2025 7:00 am
CEL-SCI Announces Closing of $2.5 Million Offering - Mar 18th, 2025 2:05 pm
CEL-SCI Announces Pricing of $2.5 Million Offering - Mar 17th, 2025 1:24 pm
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Mar 17th, 2025 6:00 am
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression - Mar 14th, 2025 6:30 am
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Feb 20th, 2025 6:00 am
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - Feb 18th, 2025 6:30 am
Cel-Sci: Fiscal Q1 Earnings Snapshot - Feb 14th, 2025 2:24 pm
CVM: Fiscal Year 2024 Results - Feb 10th, 2025 2:15 am
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Jan 14th, 2025 7:00 am